Zhengyun Zou
Fujian Medical University(CN)Nanjing University of Chinese Medicine(CN)Xuzhou Medical College(CN)Anhui Medical University(CN)Yangtze Normal University(CN)Yale University(US)Wuhan University(CN)OSE Immunotherapeutics (France)(FR)First Affiliated Hospital of Hunan University of Traditional Chinese Medicine(CN)Nanjing Drum Tower Hospital(CN)Xuzhou Central Hospital(CN)Fourth Affiliated Hospital of Guangxi Medical University(CN)Renmin Hospital of Wuhan University(CN)Fujian Provincial Cancer Hospital(CN)Hubei University of Technology(CN)Nanjing Medical University(CN)Nanjing University(CN)
Publications by Year
Research Areas
CAR-T cell therapy research, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Cancer Research and Treatments
Most-Cited Works
- → CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients(2016)302 cited
- → Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors(2019)224 cited
- PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.(2000)
- → iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer(2019)123 cited
- → No Genome-Wide Protein Sequence Convergence for Echolocation(2015)117 cited
- → Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy(2014)101 cited
- →